This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...
The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis' Advanced Accelerator Applications (AAA) subsidiary while it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback